Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Pancreatic Cancer Treatment Technology

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SILVER SPRING, Md., July 11, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), (the "Company"), an international biotechnology company and provider of natural products and cell and gene therapy solutions for the treatment of diseases, announces today the completion of the acquisition of all of the shares of Bio Blue Bird AG ("BBB"), a wholly-owned subsidiary of SG Austria Private Limited (SGA). As a result of this acquisition, BBB is now our wholly-owned subsidiary.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC